Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells

Helene S. Smith, Wainer Zoli, Annalisa Volpi, Alan Hiller, Marc Lippman, Marc E Lippman, Brian Mayall, Charles Dollbaum, Adeline J. Hackett, Dino Amadori

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

These studies describe the clinical correlations of 63 in vitro chemosensitivity assays on breast cancer cells after short-term monolayer culture. Forty-five of the assays were single agent correlations. Based on cut-off values determined empirically, the test accurately predicted resistance for 36 of 41 patients (88%) who did not respond to the drug. It also predicted sensitivity with a high degree of accuracy: 21 of 22 patients (95%) who responded to the drug tested had a sensitive assay. In five cases, two biopsies were evaluated from the same patient. Whenever assays were performed before and after treatment with a given drug, tumor cells from the second biopsy were more resistant in vitro if the patient failed on therapy. If the patient did not fail, but stopped therapy for other reasons, or if there was no intervening therapy with the tested drug, the two biopsies remained similar in drug sensitivity. These results suggest that in vitro chemosensitivity assays which accurately predict both sensitivity and resistance can be obtained with breast cancer cells after short-term culture and that further prospective trials are warranted.

Original languageEnglish
Pages (from-to)2943-2948
Number of pages6
JournalCancer Research
Volume50
Issue number10
StatePublished - May 15 1990
Externally publishedYes

Fingerprint

Breast Neoplasms
Pharmaceutical Preparations
Biopsy
Therapeutics
In Vitro Techniques
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smith, H. S., Zoli, W., Volpi, A., Hiller, A., Lippman, M., Lippman, M. E., ... Amadori, D. (1990). Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. Cancer Research, 50(10), 2943-2948.

Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. / Smith, Helene S.; Zoli, Wainer; Volpi, Annalisa; Hiller, Alan; Lippman, Marc; Lippman, Marc E; Mayall, Brian; Dollbaum, Charles; Hackett, Adeline J.; Amadori, Dino.

In: Cancer Research, Vol. 50, No. 10, 15.05.1990, p. 2943-2948.

Research output: Contribution to journalArticle

Smith, HS, Zoli, W, Volpi, A, Hiller, A, Lippman, M, Lippman, ME, Mayall, B, Dollbaum, C, Hackett, AJ & Amadori, D 1990, 'Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells', Cancer Research, vol. 50, no. 10, pp. 2943-2948.
Smith HS, Zoli W, Volpi A, Hiller A, Lippman M, Lippman ME et al. Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. Cancer Research. 1990 May 15;50(10):2943-2948.
Smith, Helene S. ; Zoli, Wainer ; Volpi, Annalisa ; Hiller, Alan ; Lippman, Marc ; Lippman, Marc E ; Mayall, Brian ; Dollbaum, Charles ; Hackett, Adeline J. ; Amadori, Dino. / Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. In: Cancer Research. 1990 ; Vol. 50, No. 10. pp. 2943-2948.
@article{2132fbae020949ef92c74014e678e7f6,
title = "Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells",
abstract = "These studies describe the clinical correlations of 63 in vitro chemosensitivity assays on breast cancer cells after short-term monolayer culture. Forty-five of the assays were single agent correlations. Based on cut-off values determined empirically, the test accurately predicted resistance for 36 of 41 patients (88{\%}) who did not respond to the drug. It also predicted sensitivity with a high degree of accuracy: 21 of 22 patients (95{\%}) who responded to the drug tested had a sensitive assay. In five cases, two biopsies were evaluated from the same patient. Whenever assays were performed before and after treatment with a given drug, tumor cells from the second biopsy were more resistant in vitro if the patient failed on therapy. If the patient did not fail, but stopped therapy for other reasons, or if there was no intervening therapy with the tested drug, the two biopsies remained similar in drug sensitivity. These results suggest that in vitro chemosensitivity assays which accurately predict both sensitivity and resistance can be obtained with breast cancer cells after short-term culture and that further prospective trials are warranted.",
author = "Smith, {Helene S.} and Wainer Zoli and Annalisa Volpi and Alan Hiller and Marc Lippman and Lippman, {Marc E} and Brian Mayall and Charles Dollbaum and Hackett, {Adeline J.} and Dino Amadori",
year = "1990",
month = "5",
day = "15",
language = "English",
volume = "50",
pages = "2943--2948",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells

AU - Smith, Helene S.

AU - Zoli, Wainer

AU - Volpi, Annalisa

AU - Hiller, Alan

AU - Lippman, Marc

AU - Lippman, Marc E

AU - Mayall, Brian

AU - Dollbaum, Charles

AU - Hackett, Adeline J.

AU - Amadori, Dino

PY - 1990/5/15

Y1 - 1990/5/15

N2 - These studies describe the clinical correlations of 63 in vitro chemosensitivity assays on breast cancer cells after short-term monolayer culture. Forty-five of the assays were single agent correlations. Based on cut-off values determined empirically, the test accurately predicted resistance for 36 of 41 patients (88%) who did not respond to the drug. It also predicted sensitivity with a high degree of accuracy: 21 of 22 patients (95%) who responded to the drug tested had a sensitive assay. In five cases, two biopsies were evaluated from the same patient. Whenever assays were performed before and after treatment with a given drug, tumor cells from the second biopsy were more resistant in vitro if the patient failed on therapy. If the patient did not fail, but stopped therapy for other reasons, or if there was no intervening therapy with the tested drug, the two biopsies remained similar in drug sensitivity. These results suggest that in vitro chemosensitivity assays which accurately predict both sensitivity and resistance can be obtained with breast cancer cells after short-term culture and that further prospective trials are warranted.

AB - These studies describe the clinical correlations of 63 in vitro chemosensitivity assays on breast cancer cells after short-term monolayer culture. Forty-five of the assays were single agent correlations. Based on cut-off values determined empirically, the test accurately predicted resistance for 36 of 41 patients (88%) who did not respond to the drug. It also predicted sensitivity with a high degree of accuracy: 21 of 22 patients (95%) who responded to the drug tested had a sensitive assay. In five cases, two biopsies were evaluated from the same patient. Whenever assays were performed before and after treatment with a given drug, tumor cells from the second biopsy were more resistant in vitro if the patient failed on therapy. If the patient did not fail, but stopped therapy for other reasons, or if there was no intervening therapy with the tested drug, the two biopsies remained similar in drug sensitivity. These results suggest that in vitro chemosensitivity assays which accurately predict both sensitivity and resistance can be obtained with breast cancer cells after short-term culture and that further prospective trials are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0025365574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025365574&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 2943

EP - 2948

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -